Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03746782 · ClinicalTrials.gov registry record

Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation

A clinical trial of Acute Coronary Syndrome, sponsored by CirQuest Labs.

Completed
Registry status
40
Enrollment target
1
Study location

NCT03746782 is a study of Acute Coronary Syndrome that has completed, run by CirQuest Labs. The registered enrollment target is 40 participants, below the 2,721-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03746782, a study of Acute Coronary Syndrome, has completed, sponsored by CirQuest Labs.

COMPLETED
Registry status
40 participants
Enrollment target
1
Study location

Study Summary

Investigating Synergistic Effects of Apixaban with Dual Anti-Platelet Therapy (DAPT) in Lowering Platelet Reactivity and Thrombin Generation

Conditions Studied

Acute Coronary Syndrome

Interventions

  • DIAGNOSTIC_TEST Flow Cytrometry; Thrombin Generation Assay

Study Locations (1)

Tennessee

  • CirQuest Labs, LLC - Memphis

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2018-07-10
Est. Completion 2019-11-08

Sponsor

CirQuest Labs

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03746782

The ClinicalTrials.gov registry entry for NCT03746782 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,721-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (99% lower). The listed sponsor is CirQuest Labs, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Flow Cytrometry; Thrombin Generation Assay is the first listed.

NCT03746782 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT03746782 about?

NCT03746782 is a clinical study titled "Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation". Investigating Synergistic Effects of Apixaban with Dual Anti-Platelet Therapy (DAPT) in Lowering Platelet Reactivity and Thrombin Generation

What is the current status of trial NCT03746782?

This trial is currently completed. The enrollment target is 40 participants. The study started on 2018-07-10. Estimated completion is 2019-11-08.

What conditions does trial NCT03746782 study?

This clinical trial studies the following conditions: Acute Coronary Syndrome.

What interventions are being tested in trial NCT03746782?

The interventions under investigation include: Flow Cytrometry; Thrombin Generation Assay (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03746782?

This trial is sponsored by CirQuest Labs, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03746782 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Coronary Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Coronary Syndrome

All registered trials for this condition

Tennessee

All trials with a study site in Tennessee

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.